U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2010
474
Substance Class Protein
Created
by admin
on Mon Mar 31 18:04:14 GMT 2025
Edited
by admin
on Mon Mar 31 18:04:14 GMT 2025
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG1
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
I031V2H011
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
TOCILIZUMAB (GENETICAL RECOMBINATION)
JAN  
Preferred Name English
TOCILIZUMAB
DASH   EMA EPAR   INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
TOCILIZUMAB [EMA EPAR]
Common Name English
tocilizumab [INN]
Common Name English
MRA
Common Name English
ROACTEMRA
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 6 RECEPTOR) (HUMAN-MOUSE MONOCLONAL MRA HEAVY CHAIN), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL MRA .KAPPA.-CHAIN, DIMER
Common Name English
R-1569
Code English
ATLIZUMAB
Common Name English
TOCILIZUMAB [MART.]
Common Name English
Tocilizumab [WHO-DD]
Common Name English
RHPM-1
Code English
TOCILIZUMAB [PURPLE BOOK CDER]
Common Name English
TOCILIZUMAB [USAN]
Common Name English
TOCILIZUMAB [JAN]
Common Name English
TOCILIZUMAB [MI]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 6 RECEPTOR) (HUMAN-MOUSE MONOCLONAL MRA HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL MRA .KAPPA.-CHAIN, DIMER
Common Name English
RG-1569
Code English
ACTEMRA
Brand Name English
RO-4877533
Code English
TOCILIZUMAB [VANDF]
Common Name English
Classification Tree Code System Code
NDF-RT N0000190480
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
LIVERTOX NBK548243
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
EMA ASSESSMENT REPORTS ROACTEMRA (AUTHORIZED: ARTHRITIS, JUVENILE RHEUMATOID)
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
NCI_THESAURUS C20401
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
FDA ORPHAN DRUG 436114
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
WHO-ATC L04AC07
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
FDA ORPHAN DRUG 589317
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
FDA ORPHAN DRUG 367812
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
EMA ASSESSMENT REPORTS ROACTEMRA (AUTHORIZED: ARTHRITIS, RHEUMATOID)
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
WHO-VATC QL04AC07
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
FDA ORPHAN DRUG 381212
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
Code System Code Type Description
INN
8394
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
PRIMARY
NCI_THESAURUS
C84217
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
PRIMARY
DRUG CENTRAL
4933
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
PRIMARY
JAPANESE REVIEW
ACTEMRA
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
PRIMARY APPROVED APRIL 2008
DAILYMED
I031V2H011
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
PRIMARY
FDA UNII
I031V2H011
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
PRIMARY
WIKIPEDIA
TOCILIZUMAB
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
PRIMARY
CAS
375823-41-9
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
PRIMARY
IUPHAR
6881
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
PRIMARY
ChEMBL
CHEMBL1237022
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
PRIMARY
MERCK INDEX
m10921
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
PRIMARY Merck Index
NDF-RT
N0000190478
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
PRIMARY Interleukin 6 Receptor Antagonists [MoA]
MESH
C502936
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
PRIMARY
SMS_ID
100000091701
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
PRIMARY
USAN
OO-55
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
PRIMARY
DRUG BANK
DB06273
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
PRIMARY
RXCUI
612865
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
PRIMARY RxNorm
LACTMED
Tocilizumab
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
PRIMARY
EVMPD
SUB20313
Created by admin on Mon Mar 31 18:04:14 GMT 2025 , Edited by admin on Mon Mar 31 18:04:14 GMT 2025
PRIMARY
From To
1_22 1_96
1_146 1_202
1_222 3_214
1_228 2_228
1_231 2_231
1_263 1_323
1_369 1_427
2_22 2_96
2_146 2_202
2_222 4_214
2_263 2_323
2_369 2_427
3_23 3_88
3_134 3_194
4_23 4_88
4_134 4_194
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_299
N 2_299
Related Record Type Details
HUMAN INTERLEUKIN-6
TARGET -> INHIBITOR
Tocilizumab-ANOH
SUB_CONCEPT->SUBSTANCE
TOCILIZUMAB BIOSIMILAR (RGB-19)
SUB_CONCEPT->SUBSTANCE
INTERLEUKIN 6 RECEPTOR
TARGET -> INHIBITOR
Tocilizumab-AAZG
SUB_CONCEPT->SUBSTANCE
BAT-1806
BIOSIMILAR -> PARENT
TOCILIZUMAB BIOSIMILAR (RGB-19)
BIOSIMILAR -> PARENT
BAT-1806
SUB_CONCEPT->SUBSTANCE
Tocilizumab-BAVI
SUB_CONCEPT->SUBSTANCE
Related Record Type Details
TOCILIZUMAB
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO ACID SUBSTITUTION [1_1] [2_1] PIDOLIC ACID SZB83O1W42
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT(ESTIMATE) CHEMICAL
Biological Half-life PHARMACOKINETIC
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966